BioWorld

Jan. 14, 2004

TKT Says It Will No Longer Seek U.S. Replagal Approval

Transkaryotic Therapies Inc. lost 23.5 percent of its stock value after announcing its decision to abandon efforts to win U.S. approval of Replagal, an enzyme replacement therapy for Fabry's disease. (BioWorld Today) Read More

Curis Inks $170M Deal To License Hedgehog Technology To Wyeth

Synta's Beefy Pipeline Gets $50M In Series C Financing

BioStratum Could Receive $80M Per Antibody In Novo Cancer Deal

Neurogen's C5a Antagonist Fails Phase IIa Asthma Trial

Acumen, Merck Sign Alzheimer's Disease Pact With $96M Potential

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...